CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $82.25 per share ($80.605 per share, net of underwriting discount). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Off ...

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, General Electric ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are t ...

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.One of our most popular services, Zacks Premium offers daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All are useful tools to find what stocks to buy, what to sell, and what are today's hottest industries.It a ...

GE Healthcare (GEHC) and MedQuest Associates recently announced their collaboration to boost multi-site outpatient imaging networks.As a result of this three-year collaboration, GE Healthcare, with its innovative technologies along with MedQuest’s outpatient imaging facilities, is set to optimize imaging solutions and provide solutions to support Theranostics.Price PerformanceFor the past six months, GEHC’s shares have gained 15.8% against the industry’s decline of 0.9%. The S&P 500 increased 11.8% in the s ...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MedQuest Associates (MedQuest), a leading owner, operator, and manager of outpatient diagnostic imaging facilities, today announced a three-year collaboration to deliver excellence in patient care by providing access to innovative technologies from GE HealthCare and the infrastructure and resources from MedQuest that are needed to optimize multi-site o ...

Key TakeawaysThe S&P 500 gained 0.2% on Tuesday, Feb. 6, 2024, as Federal Reserve officials struck a tone of cautious optimism and more companies released quarterly results.GE HealthCare shares soared as growth in imaging and patient care solutions helped drive strong earnings.Shares of FMC Corp. tumbled after the agriculture firm provided lackluster guidance, reflecting the impact of low sales volume and destocking issues.Major U.S. stock indexes posted moderate gains as more companies reported earnings re ...

GE HealthCare (GEHC) reported fourth-quarter 2023 adjusted earnings per share (EPS) of $1.18, which beat the Zacks Consensus Estimate of $1.07 by 10.3%. The bottom line, however, declined 9.9% year over year.GAAP EPS in the quarter was 88 cents, down 27.3% from the year-ago quarter’s level.Revenue DetailsThis currently Zacks Rank #3 (Hold) company reported revenues of $5.2 billion, up 5% from the prior-year quarter’s recorded number, reportedly as well as organically. The growth was driven by an improvement ...

Organic Revenue Growth*(1) 8% Approximately 4% Free Cash Flow* $1.7 billion ~$1.8 billion | --- | --- | --- | |-----------------------|-------|----------------------------------| | Adjusted EBIT Margin* | 15.1% | 15.6% - 15.9% 50 - 80 bps growth | | Adjusted ETR* 23.7% | | 23% - 25% | | Adjusted EPS* | $3.93 | $4.20 - $4.35 7% - 11% growth | © 2024 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. 13 Investing in Digital for Future Growth Imaging Ultrasound Imaging A ...

Financial Data and Key Metrics Changes - For Q4 2023, revenues reached $5.2 billion, marking a 5% year-over-year increase and 5% organic growth, following a strong 13% growth in Q4 2022 [2][16] - Adjusted EBIT margin for Q4 was 16.1%, improving by 70 basis points sequentially, while year-over-year, it remained flat due to offsetting factors [3][16] - Full year 2023 revenues totaled $19.6 billion, reflecting an 8% organic growth compared to the previous year, with adjusted EPS of $3.93, a 16% increase [16][15] Business Line Data and Key Metrics Changes - Pharmaceutical Diagnostics (PDx) saw a robust 23% organic growth in Q4, with an EBIT margin of 24.4%, up 140 basis points year-over-year [31] - Imaging segment achieved 4% organic revenue growth, with EBIT margin up 10 basis points year-over-year, driven by backlog conversion and pricing [27] - Patient Care Solutions (PCS) reported a 4% organic revenue increase, but the margin decreased by 320 basis points due to investments and prior year one-time benefits [30] - Ultrasound organic revenue declined by 2% year-over-year, with margin decline attributed to investments in AI integration [28] Market Data and Key Metrics Changes - Organic orders grew by 3% year-over-year, with a book-to-bill ratio of 1.05x, indicating healthy demand and a record backlog of $19.1 billion [51] - The overall Theranostics market is projected to grow from $9 billion to $40 billion by 2032, highlighting significant growth potential in this area [12] Company Strategy and Development Direction - The company plans to enhance its Theranostics franchise through organic and inorganic growth, including the acquisition of MIM Software to improve imaging capabilities [13][40] - Continued emphasis on R&D, with over $1 billion invested in 2023, equating to over 6% of sales, supporting innovation and future growth [5][39] - The company aims for a 4% organic revenue growth in 2024, with expectations of adjusted EBIT margin expansion of 50 to 80 basis points [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges, citing strong order intake and backlog as indicators of future performance [37][50] - The outlook for China remains cautious, with expectations of negative growth in the first half of 2024, but a return to growth anticipated in the second half [23][24] - Management highlighted the importance of compliance and operational efficiency in adapting to changing market conditions [23] Other Important Information - The company has secured multiyear enterprise deals totaling approximately $2.5 billion, enhancing its growth prospects [63] - Free cash flow for 2023 exceeded $1.7 billion, with a conversion rate of 95%, reflecting strong working capital management [17][34] Q&A Session Summary Question: How is pricing flowing through on the service book? - Management noted that service agreements are seeing similar price uplifts as hardware, maintaining a consistent ratio [7] Question: Can the company still grow revenues in Q1 given strong year-over-year comps? - Management confirmed expectations for revenue growth in Q1, albeit at a lower rate than the previous year due to challenging comparisons [21] Question: What is the outlook for sales and orders in China? - Management indicated a mixed outlook for China, with strong growth in the first half of 2023 but expecting negative growth in the first half of 2024, with a return to growth in the second half [22][23] Question: How does the company plan to monetize AI-enabled technology? - The company is exploring multiple monetization strategies, including higher value propositions for AI-enhanced products and a SaaS model for certain applications [94]